NeuroKaire
Develops blood-based tools for antidepressant selection and precision psychiatry.
The record
- Headquarters
- Kearny, New Jersey, United States, and Tel Aviv, Israel
- Region
- North America
- Vertical
- Mental & Behavioural Health
- Sub-segment
- Precision psychiatry diagnostics
- Product type
- Diagnostics
- Stage
- Series A
- Founded
- 2018
What they do
BrightKaire uses a blood draw at Quest labs or a provider office to generate patient-specific neurons. An algorithm ranks antidepressants by their effects on those neurons, and results are delivered through a provider portal. NeuroKaire reports AUC 0.81 and 84% positive predictive value. The December 2024 release says the test includes pharmacogenetic screening covering 132 drugs. The company also supports pharmaceutical and biotechnology drug development in psychiatry and neurology.
Leadership & founders
- Talia Cohen Solal
Co-founder and CEO
- Daphna Laifenfeld
Co-founder and Chief Scientific Officer
Investors
- GreyBird Ventures
- Meron Capital
- Jumpspeed Ventures
- Sapir Venture Partners
History and progression
How NeuroKaire got here, step by step.
2018
Founded as Genetika+
Talia Cohen Solal and Daphna Laifenfeld founded Genetika+.
30 September 2021
$10 million Series A
GreyBird Ventures led the round with Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan and Michael Zeisser, to fund trials and a clinical lab in Boston.
17 December 2024
$10 million to scale
GreyBird Ventures led funding with Meron Capital and Jumpspeed Ventures to scale operations and pharmaceutical partnerships.
15 November 2026
BrightKaire at HLTH
NeuroKaire showcased BrightKaire at HLTH 2026 in Las Vegas.
Key products
- BrightKaire
- A blood draw at Quest labs or a provider office generates patient-specific neurons. An algorithm ranks antidepressants by their effect on those neurons, with results in a provider portal. The company reports AUC 0.81 and 84% positive predictive value.
- Pharma and biotech services
- Precision medicine support for drug development in psychiatry and neurology.
Recent news
15 November 2026
NeuroKaire showcases BrightKaire at HLTH